Review invitation, published in Diagnostics, on the current perspective in the diagnostics development for oral cancer
|
|
Review invitation, published in Diagnostics, on the current perspective in the diagnostics development for oral cancer |
New Taipei City, August 2st, 2021. iStat Biomedical Co., Ltd. (iStat Co.), published an invited review article, current Insights into Oral Cancer Diagnostics, in Diagnosticsa.
iStat Co. is honored to be invited to write a review article with topic pertained to oral cancer diagnostics. This is a great opportunity to share important science and technology innovation, and contributes to the unmet medical need for oral precancers and oral cancers.
Oral cancer is one of the most common head and neck malignancies in the world, with overall 5-year survival rate under 50%. Oral cancer is generally preceded by oral potentially malignant disorders (OPMDs), and determining the risk of OPMD progressing to cancer remains a difficult task. To date, visual oral examination remains the routine first-line method in identifying oral lesions; however, this method has certain limitations and as a consequence, patients are either diagnosed when their cancer reaches a severe stage or a high-risk patient with OPMD is misdiagnosed and left untreated.
This article gave a broad spectrum of introduction of the currently available diagnostic methods as well as possible future applications of novel promising technologies including novel biomarkers, electronic systems, and artificial intelligence that facilitate the detection of OPMD and oral cancer at the early stage. Additionally, some of these have been translated into regulatory-approved in vitro diagnostic systems or medical devices.
- Su, Y. F., Chen, Y. J., Tsai, F. T., Li, W. C., Hsu, M. L., Wang, D. H., & Yang, C. C. (2021). Current Insights into Oral Cancer Diagnostics. Diagnostics (Basel, Switzerland), 11(7), 1287. https://doi.org/10.3390/diagnostics11071287
For more information, please visit: https://tw.epigenebio.com/
About iStat Biomedical
iStat Biomedical is a Taiwan-based biotechnology company specialized in the development and manufacturing of gene methylation assay IVD products for the early detection of cancers. iStat Biomedical develops innovative products that are primarily used in the clinical laboratories, and provides physicians with alternative solutions for clinical managements. iStat Biomedical also provides services for gene methylation detection and IVD contract manufacturing.
iStat Biomedical Co., Ltd contact:
+886-2-26963518
|
|
Review invitation, published in Diagnostics, on the current perspective in the diagnostics development for oral cancer |
New Taipei City, August 2st, 2021. iStat Biomedical Co., Ltd. (iStat Co.), published an invited review article, current Insights into Oral Cancer Diagnostics, in Diagnosticsa.
iStat Co. is honored to be invited to write a review article with topic pertained to oral cancer diagnostics. This is a great opportunity to share important science and technology innovation, and contributes to the unmet medical need for oral precancers and oral cancers.
Oral cancer is one of the most common head and neck malignancies in the world, with overall 5-year survival rate under 50%. Oral cancer is generally preceded by oral potentially malignant disorders (OPMDs), and determining the risk of OPMD progressing to cancer remains a difficult task. To date, visual oral examination remains the routine first-line method in identifying oral lesions; however, this method has certain limitations and as a consequence, patients are either diagnosed when their cancer reaches a severe stage or a high-risk patient with OPMD is misdiagnosed and left untreated.
This article gave a broad spectrum of introduction of the currently available diagnostic methods as well as possible future applications of novel promising technologies including novel biomarkers, electronic systems, and artificial intelligence that facilitate the detection of OPMD and oral cancer at the early stage. Additionally, some of these have been translated into regulatory-approved in vitro diagnostic systems or medical devices.
- Su, Y. F., Chen, Y. J., Tsai, F. T., Li, W. C., Hsu, M. L., Wang, D. H., & Yang, C. C. (2021). Current Insights into Oral Cancer Diagnostics. Diagnostics (Basel, Switzerland), 11(7), 1287. https://doi.org/10.3390/diagnostics11071287
For more information, please visit: https://tw.epigenebio.com/
About iStat Biomedical
iStat Biomedical is a Taiwan-based biotechnology company specialized in the development and manufacturing of gene methylation assay IVD products for the early detection of cancers. iStat Biomedical develops innovative products that are primarily used in the clinical laboratories, and provides physicians with alternative solutions for clinical managements. iStat Biomedical also provides services for gene methylation detection and IVD contract manufacturing.
iStat Biomedical Co., Ltd contact:
+886-2-26963518